Key result
Combined dapagliflozin and melatonin improves LVEF and reduces fibrosis more than monotherapy in post-AMI rats.
Why the study?
It was unknown whether combined dapagliflozin and melatonin therapy was superior to either monotherapy for ameliorating LV fibrosis and remodeling and improving LVEF after acute myocardial infarction.
Does combined dapagliflozin and melatonin therapy improve LVEF and ameliorate LV fibrosis in a rat model of acute myocardial infarction?
Does combined dapagliflozin and melatonin therapy improve LVEF and ameliorate LV fibrosis in a rat model of acute myocardial infarction?
Combined dapagliflozin and melatonin therapy is superior to either monotherapy in improving LVEF and inhibiting fibrosis/LV remodeling in a rat model of acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Should not yet change clinical practice; extends preclinical rationale for synergistic SGLT2i-melatonin effects on post-MI remodeling.
This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐β/Smads signaling, whereas Mel treatment significantly upregulated Nrf2/ARE signaling in ischemia–reperfusion (IR) H9C2 cells (all P< 0.001). Additionally, simultaneously silencing TGF‐β and overexpression of Nrf2 in H9C2 cells significantly suppressed fibrotic and upregulated antioxidant signaling (all P< 0.001). Adult male Sprague–Dawley rats were categorized into groups 1 (sham‐operated‐control)/2 (AMI)/3 (AMI + DAPA)/4 (AMI + Mel)/5 (AMI + DAPA‐Mel), and the hearts were harvested by day 28. By day 28 after AMI induction, the LVEF was highest in group 1, lowest in group 2, and significantly higher in group 5 than in groups 3 and 4, but it did not differ between groups 3 and 4, whereas the LV systolic/diastolic dimensions exhibited an opposite pattern of LVEF among the groups (all P< 0.0001). The protein expressions of TGF‐β/Smads signaling exhibited an opposite pattern, whereas the protein expressions of Nrf2/ARE signaling displayed an identical pattern of LVEF among the groups (all P< 0.0001). The protein expressions of oxidative‐stress/DNA‐mitochondria damaged/inflammatory biomarkers and histopathological/anatomical findings demonstrated that the infarct and fibrotic areas/LV‐chamber dimensions/cardiomyocyte size exhibited an opposite manner of LVEF among the groups (all P< 0.0001). In conclusion, combined DAPA‐Mel therapy was superior to merely one for improving LVEF and inhibiting fibrosis/LV remodeling in AMI rodents.
Sheu et al. (2026) studied this question. Combined dapagliflozin and melatonin therapy improved LV ejection fraction and reduced fibrosis significantly more than monotherapy in rats after acute myocardial infarction (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: